Inhibition of Wnt/β-Catenin pathway and Histone acetyltransferase activity by Rimonabant: a therapeutic target for colon cancer

[1]  D. Sarnataro,et al.  The Cannabinoid CB1 Receptor Antagonist Rimonabant (SR141716) Inhibits Human Breast Cancer Cell Proliferation through a Lipid Raft-Mediated Mechanism , 2006, Molecular Pharmacology.

[2]  P. Farnham,et al.  Altering cancer transcriptomes using epigenomic inhibitors , 2015, Epigenetics & Chromatin.

[3]  R. Dahiya,et al.  Frizzled homolog proteins, microRNAs and Wnt signaling in cancer , 2013, International journal of cancer.

[4]  Hoguen Kim,et al.  An Unconventional KITENIN/ErbB4-Mediated Downstream Signal of EGF Upregulates c-Jun and the Invasiveness of Colorectal Cancer Cells , 2014, Clinical Cancer Research.

[5]  S. Ward,et al.  CB1‐independent mechanisms of Δ9‐THCV, AM251 and SR141716 (rimonabant) , 2012, Journal of clinical pharmacy and therapeutics.

[6]  Tomonori Kawasaki,et al.  Hypoxia-inducible adenosine A2B receptor modulates proliferation of colon carcinoma cells. , 2010, Human pathology.

[7]  M. Washington,et al.  ERBB4 is over-expressed in human colon cancer and enhances cellular transformation. , 2015, Carcinogenesis.

[8]  F. Di Virgilio,et al.  Extracellular purines, purinergic receptors and tumor growth , 2016, Oncogene.

[9]  G. Bifulco,et al.  Structural evidence of N6-isopentenyladenosine as a new ligand of farnesyl pyrophosphate synthase. , 2014, Journal of medicinal chemistry.

[10]  D. Kimelman,et al.  β-Catenin destruction complex: insights and questions from a structural perspective , 2006, Oncogene.

[11]  J. D. den Dunnen,et al.  Genome-wide assessment of differential roles for p300 and CBP in transcription regulation , 2010, Nucleic acids research.

[12]  A. Malfitano,et al.  Cannabinoid receptor CB1 regulates STAT3 activity and its expression dictates the responsiveness to SR141716 treatment in human glioma patients' cells , 2015, Oncotarget.

[13]  R. Capasso,et al.  Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon , 2007, Journal of Molecular Medicine.

[14]  P. Fishman,et al.  Inhibition of primary colon carcinoma growth and liver metastasis by the A3 adenosine receptor agonist CF101 , 2003, British Journal of Cancer.

[15]  L. Di Croce,et al.  Interaction of endocannabinoid system and steroid Hormones in the control of colon cancer cell growth , 2012, Journal of cellular physiology.

[16]  L. Morbidelli,et al.  Genetic and pharmacologic inactivation of cannabinoid CB1 receptor inhibits angiogenesis. , 2011, Blood.

[17]  G. Bifulco,et al.  New steroids with a rearranged skeleton as (h)P300 inhibitors from the sponge Theonella swinhoei. , 2014, Organic letters.

[18]  X. Chen,et al.  Adenomatous polyposis coli (APC) differentially regulates beta-catenin phosphorylation and ubiquitination in colon cancer cells. , 2006, The Journal of biological chemistry.

[19]  H. Modjtahedi,et al.  Co-Expression of HER Family Members in Patients with Dukes’ C and D Colon Cancer and Their Impacts on Patient Prognosis and Survival , 2014, PloS one.

[20]  C. Paraskeva,et al.  The cannabinoid δ9‐tetrahydrocannabinol inhibits RAS‐MAPK and PI3K‐AKT survival signalling and induces BAD‐mediated apoptosis in colorectal cancer cells , 2007 .

[21]  Sandeep R. Bhave,et al.  GSK-3β: A Bifunctional Role in Cell Death Pathways , 2012, International journal of cell biology.

[22]  Randall T. Moon,et al.  Wnt and calcium signaling: β-Catenin-independent pathways , 2005 .

[23]  A. C. Williams,et al.  The cannabinoid delta(9)-tetrahydrocannabinol inhibits RAS-MAPK and PI3K-AKT survival signalling and induces BAD-mediated apoptosis in colorectal cancer cells. , 2007, International journal of cancer.

[24]  M. Jonsson,et al.  Cannabinoid receptor-independent cytotoxic effects of cannabinoids in human colorectal carcinoma cells: synergism with 5-fluorouracil , 2009, Cancer Chemotherapy and Pharmacology.

[25]  Xi He,et al.  Adenomatous Polyposis Coli (APC) Differentially Regulates β-Catenin Phosphorylation and Ubiquitination in Colon Cancer Cells* , 2006, Journal of Biological Chemistry.

[26]  K. Druey,et al.  Prostaglandin E2 Promotes Colon Cancer Cell Growth Through a Gs-Axin-ß-Catenin Signaling Axis , 2005, Science.

[27]  K. Varani,et al.  Adenosine receptors in colon carcinoma tissues and colon tumoral cell lines: Focus on the A3 adenosine subtype , 2007, Journal of cellular physiology.

[28]  E. Novellino,et al.  Identification of Structural Features of 2‐Alkylidene‐1,3‐Dicarbonyl Derivatives that Induce Inhibition and/or Activation of Histone Acetyltransferases KAT3B/p300 and KAT2B/PCAF , 2015, ChemMedChem.

[29]  R. Diez‐Alarcia,et al.  The inverse agonist effect of rimonabant on G protein activation is not mediated by the cannabinoid CB1 receptor: evidence from postmortem human brain. , 2012, Biochemical pharmacology.

[30]  A. Burgess,et al.  Selective inhibition of proliferation in colorectal carcinoma cell lines expressing mutant APC or activated B‐Raf , 2009, International journal of cancer.

[31]  Naoto Ueno,et al.  The TAK1-NLK Mitogen-Activated Protein Kinase Cascade Functions in the Wnt-5a/Ca2+ Pathway To Antagonize Wnt/β-Catenin Signaling , 2003, Molecular and Cellular Biology.

[32]  L. Klein-Hitpass,et al.  The first five years of the Wnt targetome. , 2008, Cellular signalling.

[33]  Nobuyuki Onishi,et al.  The receptor tyrosine kinase Ror2 is involved in non‐canonical Wnt5a/JNK signalling pathway , 2003, Genes to cells : devoted to molecular & cellular mechanisms.

[34]  R. Pertwee.  Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. , 2010, Current medicinal chemistry.

[35]  W. Sellers,et al.  Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974 , 2013, Proceedings of the National Academy of Sciences.

[36]  J. Haley,et al.  Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition , 2007, Molecular Cancer Therapeutics.

[37]  Chris Morley,et al.  Open Babel: An open chemical toolbox , 2011, J. Cheminformatics.

[38]  Sanjay Goel,et al.  PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. , 2008, Cancer research.

[39]  S. Dey,et al.  Loss of cannabinoid receptor 1 accelerates intestinal tumor growth. , 2008, Cancer research.

[40]  Gianluigi Lauro,et al.  Inverse virtual screening of antitumor targets: pilot study on a small database of natural bioactive compounds. , 2011, Journal of natural products.

[41]  A. Silver,et al.  The opposing roles of Wnt-5a in cancer , 2009, British Journal of Cancer.

[42]  Heather R. Roberts,et al.  The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. , 2009, Carcinogenesis.

[43]  M. Montecino,et al.  Wnt/β-Catenin Signaling Enhances Cyclooxygenase-2 (COX2) Transcriptional Activity in Gastric Cancer Cells , 2011, PloS one.

[44]  E. Novellino,et al.  A novel cell-permeable, selective, and noncompetitive inhibitor of KAT3 histone acetyltransferases from a combined molecular pruning/classical isosterism approach. , 2015, Journal of medicinal chemistry.

[45]  C. Harris,et al.  Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways. , 2003, Cancer research.

[46]  R. Mancinelli,et al.  The endocannabinoid anandamide inhibits cholangiocarcinoma growth via activation of the noncanonical Wnt signaling pathway. , 2008, American journal of physiology. Gastrointestinal and liver physiology.

[47]  F. Borrelli,et al.  Rimonabant inhibits human colon cancer cell growth and reduces the formation of precancerous lesions in the mouse colon , 2009, International journal of cancer.

[48]  W. Weis,et al.  The β-catenin destruction complex. , 2013, Cold Spring Harbor perspectives in biology.

[49]  F. Ciruela,et al.  Striatal Adenosine A2A and Cannabinoid CB1 Receptors Form Functional Heteromeric Complexes that Mediate the Motor Effects of Cannabinoids , 2007, Neuropsychopharmacology.

[50]  Jun Yu,et al.  WNT5A Exhibits Tumor-Suppressive Activity through Antagonizing the Wnt/β-Catenin Signaling, and Is Frequently Methylated in Colorectal Cancer , 2008, Clinical Cancer Research.

[51]  Ethan Lee,et al.  Selective small molecule targeting β-catenin function discovered by in vivo chemical genetic screen. , 2013, Cell reports.

[52]  Y. Minami,et al.  Receptor Tyrosine Kinase Ror2 Mediates Wnt5a-induced Polarized Cell Migration by Activating c-Jun N-terminal Kinase via Actin-binding Protein Filamin A* , 2008, Journal of Biological Chemistry.

[53]  R. Nusse,et al.  Purified Wnt5a Protein Activates or Inhibits β-Catenin–TCF Signaling Depending on Receptor Context , 2006, PLoS biology.

[54]  Ling Wang,et al.  The structural basis of protein acetylation by the p300/CBP transcriptional coactivator , 2008, Nature.

[55]  G. Bifulco,et al.  Discovery and synthesis of namalide reveals a new anabaenopeptin scaffold and peptidase inhibitor. , 2012, Journal of medicinal chemistry.

[56]  F. Cianchi,et al.  Cannabinoid Receptor Activation Induces Apoptosis through Tumor Necrosis Factor α–Mediated Ceramide De novo Synthesis in Colon Cancer Cells , 2008, Clinical Cancer Research.

[57]  Yibing Yan,et al.  HSP105 Recruits Protein Phosphatase 2A To Dephosphorylate β-Catenin , 2015, Molecular and Cellular Biology.

[58]  J. Abreu,et al.  Inhibition of GSK3 Phosphorylation of β-Catenin via Phosphorylated PPPSPXS Motifs of Wnt Coreceptor LRP6 , 2009, PloS one.

[59]  Arthur J. Olson,et al.  AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..

[60]  Marco Beccuti,et al.  The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets , 2015, Nature Communications.

[61]  C. Sakamoto,et al.  Localization of phosphorylated ErbB1-4 and heregulin in colorectal cancer , 2014, BMC Cancer.

[62]  S. Paladino,et al.  Anandamide inhibits the Wnt/β-catenin signalling pathway in human breast cancer MDA MB 231 cells. , 2012, European journal of cancer.

[63]  M. Caraglia,et al.  Synergistic inhibition of human colon cancer cell growth by the cannabinoid CB1 receptor antagonist rimonabant and oxaliplatin. , 2009, Oncology reports.

[64]  G. Bifulco,et al.  Inverse Virtual Screening allows the discovery of the biological activity of natural compounds. , 2012, Bioorganic & medicinal chemistry.

[65]  Helmut Blum,et al.  Comprehensive analysis of β-catenin target genes in colorectal carcinoma cell lines with deregulated Wnt/β-catenin signaling , 2014, BMC Genomics.

[66]  J. Lanciego,et al.  Neuroprotective potential of adenosine A2A and cannabinoid CB1 receptor antagonists in an animal model of Parkinson disease. , 2014, Journal of neuropathology and experimental neurology.

[67]  R. Moon,et al.  WNT signalling pathways as therapeutic targets in cancer , 2012, Nature Reviews Cancer.

[68]  J. Powell,et al.  A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy , 2015, Computational and structural biotechnology journal.